Nutex Health (NUTX) Q4 2024 earnings summary

Executive summary

• Achieved record annual revenue of $479.9M in 2024, up 94% year-over-year, with net income of $52.2M versus a net loss of $45.8M in 2023.

• Fourth quarter revenue reached $257.6M, a 270% increase from Q4 2023; net income for Q4 was $61.7M compared to a net loss of $31.6M in Q4 2023.

• Significant revenue growth was driven by arbitration efforts, contributing $169.7M in 2024 and representing over 70% of the annual increase.

• Expanded network to 24 hospitals across 11 states, opening four new facilities in 2024.

• Hospital Division visits rose 16.9% year-over-year to 168,388; mature hospitals saw a 6.5% increase in visits.

Financial highlights

• Full-year 2024 revenue reached $479.9M, up 94% year-over-year; adjusted EBITDA rose over 1,000% to $123.7M.

• Operating income for 2024 was $130.6M, up from a $31.8M loss in 2023.

• Q4 2024 revenue grew 270% to $257.6M; gross profit margin improved to 55% from 18.9% in Q4 2023.

• Net income swung to $52M in 2024 from a $46M loss in 2023.

• Net cash from operating activities increased to $23.2M from just over $1M in 2023.

Outlook and guidance

• Arbitration revenue recognition will be spread more evenly across quarters in 2025 as processes mature.

• Three new hospitals scheduled to open in late 2025, with additional pipeline through 2028.

• Mature hospitals expected to achieve single-digit volume growth, with service line expansion driving further gains.

• Management expects continued operational optimization and a lean cost structure to support sustained growth in 2025.

• Arbitration initiatives are expected to maintain higher reimbursement rates per visit.